Aquestive Therapeutics (NASDAQ:AQST) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

by · The Cerbat Gem

Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) announced its earnings results on Monday. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01), Zacks reports. The firm had revenue of $13.54 million for the quarter, compared to the consensus estimate of $12.69 million. During the same period in the prior year, the company posted ($0.03) EPS.

Aquestive Therapeutics Stock Down 6.8 %

Shares of AQST traded down $0.35 during trading hours on Tuesday, hitting $4.80. The company had a trading volume of 2,193,653 shares, compared to its average volume of 1,748,301. Aquestive Therapeutics has a 52-week low of $1.52 and a 52-week high of $6.23. The stock’s 50 day moving average price is $4.90 and its 200 day moving average price is $3.82. The firm has a market cap of $437.09 million, a P/E ratio of -13.89 and a beta of 2.82.

Wall Street Analyst Weigh In

A number of research firms have recently commented on AQST. Leerink Partners lifted their target price on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. JMP Securities reissued a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research report on Friday, October 25th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $8.83.

Read Our Latest Stock Report on Aquestive Therapeutics

About Aquestive Therapeutics

(Get Free Report)

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

Featured Articles